Brokers Issue Forecasts for AstraZeneca FY2025 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for AstraZeneca in a note issued to investors on Monday, November 18th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $5.28 for the year, down from their previous forecast of $5.31. The consensus estimate for AstraZeneca’s current full-year earnings is $4.07 per share. Leerink Partnrs also issued estimates for AstraZeneca’s FY2026 earnings at $6.05 EPS.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 EPS.

Other analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $63.39 on Tuesday. The firm has a market capitalization of $196.55 billion, a P/E ratio of 30.33, a P/E/G ratio of 1.17 and a beta of 0.47. The firm’s 50-day moving average price is $74.68 and its 200-day moving average price is $78.15. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca has a 1-year low of $60.47 and a 1-year high of $87.68.

Hedge Funds Weigh In On AstraZeneca

Large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its position in AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after buying an additional 9,002,450 shares during the period. Swedbank AB bought a new position in shares of AstraZeneca during the 1st quarter valued at approximately $186,127,000. Manning & Napier Advisors LLC purchased a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $188,476,000. Bank of Montreal Can raised its holdings in shares of AstraZeneca by 109.6% in the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after purchasing an additional 1,605,758 shares during the period. Finally, Hsbc Holdings PLC lifted its stake in AstraZeneca by 750.3% in the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after purchasing an additional 1,132,362 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.